Boris Pasche, MD, PhD, FACP| Boris Pasche, MD, PhD, FACP |
 |
 |
|
Rank:  Professor and Division Director Division: Hematology & Oncology Campus Address: NP 2566 Mailing Address: 1720 2nd Avenue South, NP2540 Birmingham, AL 35294-3300 Phone: (205) 934-9591 Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816. Departmental Affiliation(s): Primary: Medicine Medical Schools: Karolinska Institute, Stockholm, Sweden University of Lausanne, Switzerland Internal Medicine Residency: The New York Hospital, Cornell Medical Center Fellowship: Hematology/Oncology, Memorial Sloan-Kettering Caner Center and the New York Hospital, Cornell University Medical College Other Education: PhD, Karolinska Institute, Stockholm, Sweden Certifications: Board certified in Medical Oncology Biosketch: Positions and Employment: November 1989- Research fellow in the laboratory of Dr. Joseph Loscalzo May 1992 Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School January 1996- Research fellow in the laboratory of Dr. Joan Massagué June 2000 Cell Biology Program, Howard Hughes Medical Institute and Sloan-Kettering Institute for Cancer Research Graduate Medical Training June 1992-June 1994 Internship and Residency in Medicine, The New York Hospital Cornell Medical Center July 1994-June 1997 Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer and the New York Hospital, Cornell University Medical College Clinical Appointments 1993-2000 Assistant Physician I, The New York Hospital and the Memorial Sloan-Kettering Cancer Center-Cornell University Medical College 2001-2008 Attending Physician, Northwestern Memorial Hospital 2008- Attending Physician, UAB Hospitals Academic Appointments 1989-1992 Research Fellow in Medicine, Harvard Medical School 1992-2000 Clinical Associate in Medicine, Cornell University Medical College 2001-2005 Assistant Professor of Medicine, Northwestern University Feinberg School of Medicine 2002-2008 Director, Cancer Genetics Program, Robert H. Lurie Comprehensive Cancer Center and Northwestern University Feinberg School of Medicine 2006-2008 Associate Professor of Medicine, Northwestern University Feinberg School of Medicine 2006-2007 Co-Leader, Cancer Genes and Molecular Targeting Program, Robert H. Lurie Comprehensive Cancer Center 2008 Leader, Cancer Genes and Molecular Targeting Program, Robert H. Lurie Comprehensive Cancer Center 2008- Professor of Medicine with Tenure and Director, Division of Hematology/Oncology Division, The University of Alabama at Birmingham 2008-2009 Associate Director for Translational Research, The University of Alabama Comprehensive Cancer Center 2008- Martha Ann and David L. May Endowed Chair in Cancer Research 2009-2011 Deputy Director, The University of Alabama Comprehensive Cancer Center 2010- Adjunct Professor, Department of Medicine, Northwestern University Feinberg School of Medicine Editorial Positions 2003- Contributing Editor, The Journal of the American Medical Association (JAMA) 2004- Editor, The Journal of Experimental and Clinical Cancer Research 2012- Editor, Cancer Hallmarks Grant Review Panels 2004- Member, Breast Cancer Center of Excellence, Era of Hope Scholar Award and Targeted Therapies Review Panels, Department of Defense 2007, 2012 Grant reviewer (adhoc), Istituto Toscano Tumori, Florence, Italy 2008 Member, Komen for the Cure Pathobiology-1 Review Panel 2008-2009 Adhoc member, NCI Cancer Genetics Study Section 2008 Member, AACR Colorectal Cancer Review Committee 2009 Member, Komen for the Cure, Targeted Therapies Committee 2010- Chair, Department of Defense Colorectal Cancer Review panel 2010-2016 Member, NCI Cancer Genetics Study Section 2010 Adhoc member, NCI Cancer Health Disparities Study Section 2010 Adhoc member, NCI U01 grant review panel 2011 Adhoc member, Special Emphasis Panel/Scientific Review Group 2011/05 ZCA1 SRLB‐1 (M1) 2011-2012 AACR Clinical and Translational Research Grants Scientific Review Committee 2012 Adhoc reviewer for the Swiss Cancer League Advisory Committees 2005-2006 Member, Special Committee Investigating Allegations of Scientific Misconduct, Northwestern University Office of Research Integrity 2004-2008 Member, NU Biotechnology Laboratory Advisory Board 2003- Member, Cancer Genetics/Familial Assessment Panel: Breast and Ovarian, National Comprehensive Cancer Network (NCCN) 2003-2006 Member, Cancer Education Committee, Tumor Biology/Human Genetics, The American Society of Clinical Oncology (ASCO) 2001- Member, Laboratory Science Gastrointestinal Committee, Eastern Cooperative Oncology Group (ECOG) 2001-2008 Member, NUgene advisory committee 2001-2008 Member, Clinical Protocol Review and Monitoring Committee, Northwestern University Feinberg School of Medicine 2010 Advisor and Reviewer, The Holden Comprehensive Cancer Center, The University of Iowa 2010 Amgen Vectibix advisory board Elected Memberships 2004 Fellow of The American College of Physicians-The American Society of Internal Medicine (ACP-ASIM) 2007 The American Society for Clinical Investigation (ASCI) 2012 American Clinical and Climatological Association Additional Research Experience 1983-1986 Clinical Trial Director, Symtonic, S.A., Renens, Switzerland 1986-2001 Chief Scientific Officer, Symtonic S.A., Renens, Switzerland 1992-1996 President, Symtonic USA, Inc., New York, New York 2007- Founder and member, TheraBionic LLC, Chicago, IL 2010- Member of the Board, The Foundation for Research on Information Technologies in Society (IT'IS) USA, Inc., Annapolis, MD Teaching Experience 2001 Medical Genetics lecture, graduate program of Molecular Biology, Evanston campus 2000-2008 Cancer Genetics Lectures, part of the Molecular Medicine Course 2002-2008 Genetics of colorectal cancer, part of 1st year medical student curriculum 2002-2008 Cancer genetics lecture: Northwestern graduate program of genetic counseling 2002-2008 The genetics of breast cancer lecture as part of the "Advanced Topics in Breast Cancer Course", Northwestern University Graduate Program 2010- Cancer genetics lecture: UAB graduate program of medical sciences Honors 1989 Young Scientist Merit Award, XIIth Congress of the International Society on Thrombosis and Hemostasis, Tokyo, Japan 1991 Young Investigator Merit Award, XIIIth Congress of the International Society on Thrombosis and Hemostasis, Amsterdam, The Netherlands 1992 Trainee Investigator Award for Excellence in Scientific Research, American Federation for Clinical Research, American Society for Clinical Investigation, American Federation for Clinical Research, Baltimore, MD 1997 First appearance in Marquis Who's Who in the East, 26th Edition 2004 First appearance in Marquis Who's Who in America, 58th Edition 2005 The Ohio State University Human Cancer Genetics Program Commemorative Medal 2008 First appearance in Marquis Who's Who in the World, 26th Edition 2009 First appearance in Marquis Who's Who in Healthcare and Medicine, 6th Edition 2009 First appearance in Castle Connolly's Top Doctors Research Description Studies of twins indicate that approximately 27% of breast cancers and 35% of colorectal cancers are inherited. High-penetrance tumor susceptibility genes only account for a small fraction of these common cancers. The remainder of the unexplained familial risk is presumably due to other high penetrance genes but polygenic mechanisms and low penetrance tumor susceptibility genes are likely to account for a greater proportion of familial breast and colorectal cancers. In a search for mutations of the type I TGF-β receptor (TGFBR1) we have identified a common variant, TGFBR1*6A, which has a deletion of three GCG triplets coding for alanine within a nine alanine (9A) repeat of TGFBR1 signal sequence. In normal epithelial cells TGFBR1*6A mediates TGF-β growth inhibitory signals less effectively than TGFBR1 and in cancer cells it may switch growth-inhibitory signals into growth-stimulatory signals. This important allele is emerging as a common breast and colon cancer susceptibility allele. Using a novel mouse model of Tgfbr1 haploinsufficiency we have shown that constitutively decreased Tgfbr1 signaling is a potent modifier of colorectal cancer in mice and humans. This led to the identification of TGFBR1 haplotypes associated with colorectal cancer and non-small cell lung cancer risk. We have also pioneered the use of amplitude-modulated electromagnetic field as a novel therapeutic approach in oncology. Our lab focuses on the role of the Transforming Growth Factor Beta (TGF-β) pathway in cancer development and progression with a focus on naturally-occurring variants such as TGFBR1*6A and constitutively decreased expression of TGFBR1. We are developing novel in vitro and in vivo models of radiofrequency electromagnetic fields exposure to assess the mechanism of action of amplitude-modulated electromagnetic fields in cancer. Publications: See a listing of publications on PubMed, a service of the National Library of Medicine. |